Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

A recent study highlights how DNA microarray technology enables high-throughput gene analysis, supporting variation detection, expression profiling, and clinical research. By refining probe design and ...

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID. Clinically significant CNVs were identified in 30% ...

Join us for an insightful webinar on the use of polygenic risk scores (PRS) for cardiovascular disease (CVD). The analysis of genetic variation across large populations plays a crucial role in ...

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...

According to latest report, the global DNA and gene chip market size is calculated at USD 11.44 billion in 2024 and is projected to hit around USD 30.72 billion by 2033, expanding at a CAGR of 11.6% ...

As per precedence Research, the global DNA microarray market size is projected to grow approximately USD 6.13 billion by 2034 from valued at USD 2.28 billion in 2023. It is expanding at a CAGR of 9.4% ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...